Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €15.71 EUR
Change Today -0.076 / -0.48%
Volume 280.0
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
€15.62
Previous Close
€15.79
Day High
€15.77
Day Low
€15.38
52 Week High
04/10/15 - €17.45
52 Week Low
10/15/14 - €8.69
Market Cap
21.1B
Average Volume 10 Days
38.0
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

24,000 Employees
Last Reported Date: 02/25/15
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $921.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $450.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Executive Vice President and President of Rhy...
Total Annual Compensation: $454.1K
Senior Vice President and President of Interv...
Total Annual Compensation: $392.8K
Compensation as of Fiscal Year 2014.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Intangible Asset Impairment Charges for the Second Quarter Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter Ending September 30, 2015; Revised Earnings Guidance for the Full Year Ending December 31, 2015

Boston Scientific Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, net sales were $1.843 billion against $1.873 billion last year. This represents 6% operational revenue growth (constant currency basis, excluding divested businesses) and a decrease of 2% on a reported basis, all compared to the prior year period. Operating income was $219 million against operating loss of $69 million last year. Income before income taxes was $105 million against loss before income taxes of $104 million last year. Net income was $102 million or $0.08 per basic and diluted share against $4 million last year. Adjusted net income was $294 million or $0.22 per diluted share against $285 million or $0.21 per diluted share last year. Capital expenditures were $46 million in second quarter of 2015 compared to $64 million in second quarter of last year. The decrease is attributable to timing. Adjusted free cash flow for the quarter was $406 million compared to $262 million in second quarter of last year. This increase was primarily due to higher adjusted operating profit, lower capital expenditures and a continued focus on working capital management. For the six months, net sales were $3.611 billion against $3.647 billion last year. Operating income was $243 million against $128 million last year. Income before income taxes was $54 million against $42 million last year. Net income was $101 million or $0.07 per diluted share against $137 million or $0.10 per basic and diluted share last year. Adjusted net income was $580 million or $0.43 per diluted share against $553 million or $0.41 per diluted share last year. For the quarter, intangible asset impairment charges was $9 million against $110 million last year. For the full year ending December 31, 2015, the company now estimates revenue to be in a range of $7.275 billion to $7.375 billion compared to prior guidance of $7.225 billion to $7.375 billion, which versus the prior year period represents change in a range of negative 1% to 0% on a reported basis and a growth range of approximately 4% to 6% on an operational basis. The company now estimates income on a GAAP basis in a range of $0.28 per share to $0.34 per share compared to prior guidance of $0.32 per share to $0.38 per share, and continues to estimate adjusted earnings, excluding intangible asset impairment charges, debt extinguishment charges, acquisition- and divestiture-, litigation-, and restructuring-related net charges, pension termination charges, and amortization expense, in a range of $0.88 per to $0.92 per share. The company expects restructuring-related charges of $0.06 per share and amortization expense of $0.28 per share against previous guidance for restructuring-related charges of $0.08 per share and amortization expense of $0.28 per share. The company expects CapEx to be roughly $260 million for the full year 2015. The company expects full year 2015 adjusted free cash flow to be approximately $1.3 billion. The company expects full year 2015 adjusted tax rate to be in the range of 13% to 15%. For the third quarter ending September 30, 2015, the company estimates sales in a range of $1.790 billion to $1.840 billion. The company estimates earnings on a GAAP basis in a range of $0.10 per share to $0.13 per share. Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related net charges and amortization expense, are estimated in a range of $0.21 per share to $0.23 per share. The company expects restructuring-related charges of $0.02 per share and amortization expense of $0.07 per share. The company expects adjusted gross margin for the third quarter to be in a range of 71.5% to 72.5%, reflecting the favorable gross margin profile of key new product launches. The company expects adjusted operating margin in the third quarter to be approximately 22.5%, plus or minus 25 basis point.

Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology

Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions. The resorbable polymer scaffold incorporates several key design elements from the Boston Scientific SYNERGY™ Stent System, including a resorbable polymer and an ultrathin everolimus coating which is applied abluminally (on the exterior) to the scaffold. It also features a delivery system built with Boston Scientific expertise designed to facilitate improved acute performance.

Boston Scientific Corporation Elects Donna A. James to Board of Directors

Boston Scientific Corporation announced the election of Donna A. James to its board of directors, effective immediately. Ms. James currently serves as a director of Time Warner Cable Inc., L Brands Inc., Marathon Petroleum Inc., as well as FIS Group. Donna A. James is the founder and managing director of Lardon & Associates LLC. Ms. James has more than 30 years of diverse management and leadership experience, including serving as the former president of Nationwide Strategic Investments, a division of Nationwide Mutual Insurance Company, where she had direct responsibility for developing and executing strategies for U.S. and global financial services subsidiaries and affiliates. Ms. James is also the founder and chair of The Center for Healthy Families.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:GR €15.71 EUR -0.076

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,867 JPY +15.00
Becton Dickinson and Co $152.15 USD +0.15
Olympus Corp ¥4,750 JPY +5.00
St Jude Medical Inc $73.82 USD -0.09
Zimmer Biomet Holdings Inc $104.07 USD -0.78
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 3.5x
Price/Cash Flow 79.2x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.